KCT0006050
Completed
未知
Metabolomics approach for evaluating effect of herbal medicines for female infertility (subtitle: Metabolic alterations after Dangguijakyaksan administration in women with mild menstrual pain)
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Daegu Haany University
- Enrollment
- 36
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Women of childbearing age over 19
- •2\) Those who are within 20% of the ideal weight calculated by Broca's formula
- •3\) Those with regular menstrual cycles (within 28 days ± 7 days)
- •4\) Those who complain of primary dysmenorrhea with mild (visual analog scale (VAS) less than 40mm) for at least 6 months during screening
- •5\) Medically without congenital or chronic disease
- •6\) Those who are judged to be suitable for the subject through medical examination (typical items such as interview, blood pressure, physical examination, blood test, blood chemistry test, urine test, serum test, etc.)
- •7\) Among applicants who are highly likely to become pregnant, those who are not pregnant by the pregnancy test at the time of medical examination, and those who use medically acceptable contraception other than hormonal contraception until the end of the study
- •8\) Applicants who can participate in the entire clinical trial process
- •9\) A person who has fully explained the purpose, content, and drug of the clinical trial for this clinical trial, and a person who decides to participate in the clinical trial and gives written consent.
Exclusion Criteria
- •1\) Those who refuse written consent or do not have the ability to consent in writing
- •2\) Pregnant or lactating women
- •3\) Persons who use hormonal contraception among medically acceptable birth control methods (e.g., implanon, intrauterine device insertion (e.g., mirena), oral contraceptives)
- •4\) Those who have undergone gastric acid secretion suppression surgery or gastric or esophageal surgery that may affect the absorption of clinical trial drugs (except for simple perforation, appendectomy, and cholecystectomy)
- •5\) Those with gastrointestinal diseases (Crohn's disease, ulcers, acute/chronic pancreatitis) that may affect the absorption of investigational drugs
- •6\) Those who have been diagnosed with clinically significant systemic diseases (liver, kidney, nervous system, respiratory system, cardiovascular system, urinary system, endocrine system), malignant tumor, or mental illness.
- •7\) Those who fall under frequent menstruation (period less than 21 days) or rare menstruation (period exceeding 35 days)
- •8\) Those who showed clinical abnormalities in the screening test, especially those who showed the following test results
- •Hemoglobin \<11\.0 g/dL
- •AST or ALT value exceeds 1\.5 times the upper limit of the laboratory's normal range
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Study the effect of CAPRIDIN in the metabolic treatment of drug-resistant epilepsyIRCT20170315033086N11Shahid Beheshti University of Medical Sciences10
Completed
Not Applicable
Metabolome analysis in association with the effects of Inchinkoto, a herbal medicine.The patients who undergo percutaneous transhepatic biliary drainage (PTBD) or endoscopic nasobiliary drainage (ENBD) due to biliary obstruction. Among the, patients who were included the study "The association between the intestinal microenvironment and choleretic effects of Inchinkoto. (UMIN 000013250) with blood and bile sampling.JPRN-UMIN000020274agoya University Graduate School of Medicine46
Recruiting
Not Applicable
Effect of Curcumin, Vitamin D and herbal oil on Multiple SclerosisMultiple Sclerosis.Multiple sclerosisIRCT20170430033730N6Qazvin University of Medical Sciences60
Not yet recruiting
Phase 4
Assessment of Pharmacokinetic Interactions and Therapeutic Effect of Chandraprabha vati with GlimepirideCTRI/2024/04/065273SRM College of Pharmacy SRM Institute of Science and Technology
Active, not recruiting
Phase 1
Metabolic and Molecular Response Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal JunctioEUCTR2014-000860-16-DETechnische Universität München Fakultaet fuer Medizin120